Log in
NASDAQ:NEO

NeoGenomics Competitors

$42.13
-0.62 (-1.45 %)
(As of 10/21/2020 12:00 AM ET)
Add
Compare
Today's Range
$41.37
Now: $42.13
$43.17
50-Day Range
$34.54
MA: $37.67
$43.94
52-Week Range
$19.43
Now: $42.13
$44.58
Volume569,389 shs
Average Volume907,827 shs
Market Capitalization$4.65 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.8

Competitors

NeoGenomics (NASDAQ:NEO) Vs. COO, TDOC, HOLX, TFX, SNN, and BIO

Should you be buying NEO stock or one of its competitors? Companies in the sector of "medical" are considered alternatives and competitors to NeoGenomics, including Cooper Companies (COO), Teladoc Health (TDOC), Hologic (HOLX), Teleflex (TFX), Smith & Nephew (SNN), and Bio-Rad Laboratories (BIO).

Cooper Companies (NYSE:COO) and NeoGenomics (NASDAQ:NEO) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

Risk & Volatility

Cooper Companies has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500. Comparatively, NeoGenomics has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Cooper Companies and NeoGenomics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cooper Companies04802.67
NeoGenomics011013.00

Cooper Companies presently has a consensus target price of $339.9167, indicating a potential downside of 2.54%. NeoGenomics has a consensus target price of $37.1818, indicating a potential downside of 11.75%. Given Cooper Companies' higher possible upside, equities research analysts plainly believe Cooper Companies is more favorable than NeoGenomics.

Valuation and Earnings

This table compares Cooper Companies and NeoGenomics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cooper Companies$2.65 billion7.01$466.70 million$12.3528.24
NeoGenomics$408.83 million11.38$8.01 million$0.23183.17

Cooper Companies has higher revenue and earnings than NeoGenomics. Cooper Companies is trading at a lower price-to-earnings ratio than NeoGenomics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cooper Companies and NeoGenomics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cooper Companies11.40%13.19%7.46%
NeoGenomics-1.33%0.73%0.51%

Institutional and Insider Ownership

88.8% of Cooper Companies shares are owned by institutional investors. Comparatively, 91.7% of NeoGenomics shares are owned by institutional investors. 1.4% of Cooper Companies shares are owned by company insiders. Comparatively, 6.5% of NeoGenomics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Cooper Companies beats NeoGenomics on 9 of the 15 factors compared between the two stocks.

Teladoc Health (NYSE:TDOC) and NeoGenomics (NASDAQ:NEO) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

Volatility & Risk

Teladoc Health has a beta of 0.25, suggesting that its stock price is 75% less volatile than the S&P 500. Comparatively, NeoGenomics has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500.

Institutional & Insider Ownership

87.4% of Teladoc Health shares are owned by institutional investors. Comparatively, 91.7% of NeoGenomics shares are owned by institutional investors. 3.4% of Teladoc Health shares are owned by company insiders. Comparatively, 6.5% of NeoGenomics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Teladoc Health and NeoGenomics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Teladoc Health$553.31 million32.50$-98,860,000.00($1.49)-145.48
NeoGenomics$408.83 million11.38$8.01 million$0.23183.17

NeoGenomics has lower revenue, but higher earnings than Teladoc Health. Teladoc Health is trading at a lower price-to-earnings ratio than NeoGenomics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Teladoc Health and NeoGenomics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Teladoc Health0111702.61
NeoGenomics011013.00

Teladoc Health currently has a consensus target price of $214.5714, suggesting a potential downside of 1.01%. NeoGenomics has a consensus target price of $37.1818, suggesting a potential downside of 11.75%. Given Teladoc Health's higher possible upside, analysts plainly believe Teladoc Health is more favorable than NeoGenomics.

Profitability

This table compares Teladoc Health and NeoGenomics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Teladoc Health-13.22%-9.54%-5.71%
NeoGenomics-1.33%0.73%0.51%

Summary

NeoGenomics beats Teladoc Health on 10 of the 15 factors compared between the two stocks.

Hologic (NASDAQ:HOLX) and NeoGenomics (NASDAQ:NEO) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Hologic and NeoGenomics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Hologic04902.69
NeoGenomics011013.00

Hologic currently has a consensus target price of $67.1538, suggesting a potential upside of 1.98%. NeoGenomics has a consensus target price of $37.1818, suggesting a potential downside of 11.75%. Given Hologic's higher possible upside, analysts plainly believe Hologic is more favorable than NeoGenomics.

Profitability

This table compares Hologic and NeoGenomics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Hologic20.03%31.40%10.38%
NeoGenomics-1.33%0.73%0.51%

Volatility & Risk

Hologic has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500. Comparatively, NeoGenomics has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500.

Institutional & Insider Ownership

93.7% of Hologic shares are owned by institutional investors. Comparatively, 91.7% of NeoGenomics shares are owned by institutional investors. 1.0% of Hologic shares are owned by company insiders. Comparatively, 6.5% of NeoGenomics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Hologic and NeoGenomics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hologic$3.37 billion5.06$-203,600,000.00$2.4327.10
NeoGenomics$408.83 million11.38$8.01 million$0.23183.17

NeoGenomics has lower revenue, but higher earnings than Hologic. Hologic is trading at a lower price-to-earnings ratio than NeoGenomics, indicating that it is currently the more affordable of the two stocks.

Summary

Hologic beats NeoGenomics on 9 of the 15 factors compared between the two stocks.

NeoGenomics (NASDAQ:NEO) and Teleflex (NYSE:TFX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

Analyst Ratings

This is a summary of recent ratings for NeoGenomics and Teleflex, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NeoGenomics011013.00
Teleflex01902.90

NeoGenomics currently has a consensus target price of $37.1818, suggesting a potential downside of 11.75%. Teleflex has a consensus target price of $389.40, suggesting a potential upside of 8.45%. Given Teleflex's higher possible upside, analysts clearly believe Teleflex is more favorable than NeoGenomics.

Profitability

This table compares NeoGenomics and Teleflex's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NeoGenomics-1.33%0.73%0.51%
Teleflex18.99%17.15%7.91%

Risk and Volatility

NeoGenomics has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500. Comparatively, Teleflex has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500.

Institutional and Insider Ownership

91.7% of NeoGenomics shares are owned by institutional investors. Comparatively, 91.3% of Teleflex shares are owned by institutional investors. 6.5% of NeoGenomics shares are owned by company insiders. Comparatively, 2.2% of Teleflex shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares NeoGenomics and Teleflex's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NeoGenomics$408.83 million11.38$8.01 million$0.23183.17
Teleflex$2.60 billion6.44$461.47 million$11.1532.20

Teleflex has higher revenue and earnings than NeoGenomics. Teleflex is trading at a lower price-to-earnings ratio than NeoGenomics, indicating that it is currently the more affordable of the two stocks.

Summary

Teleflex beats NeoGenomics on 9 of the 15 factors compared between the two stocks.

NeoGenomics (NASDAQ:NEO) and Smith & Nephew (NYSE:SNN) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

Analyst Ratings

This is a summary of recent ratings for NeoGenomics and Smith & Nephew, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NeoGenomics011013.00
Smith & Nephew23502.30

NeoGenomics currently has a consensus target price of $37.1818, suggesting a potential downside of 11.75%. Smith & Nephew has a consensus target price of $42.00, suggesting a potential upside of 10.38%. Given Smith & Nephew's higher possible upside, analysts clearly believe Smith & Nephew is more favorable than NeoGenomics.

Profitability

This table compares NeoGenomics and Smith & Nephew's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NeoGenomics-1.33%0.73%0.51%
Smith & NephewN/AN/AN/A

Risk and Volatility

NeoGenomics has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500. Comparatively, Smith & Nephew has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500.

Institutional and Insider Ownership

91.7% of NeoGenomics shares are owned by institutional investors. Comparatively, 9.1% of Smith & Nephew shares are owned by institutional investors. 6.5% of NeoGenomics shares are owned by company insiders. Comparatively, 1.0% of Smith & Nephew shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares NeoGenomics and Smith & Nephew's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NeoGenomics$408.83 million11.38$8.01 million$0.23183.17
Smith & Nephew$5.14 billion3.24$600 million$2.0418.65

Smith & Nephew has higher revenue and earnings than NeoGenomics. Smith & Nephew is trading at a lower price-to-earnings ratio than NeoGenomics, indicating that it is currently the more affordable of the two stocks.

Summary

NeoGenomics beats Smith & Nephew on 9 of the 15 factors compared between the two stocks.

NeoGenomics (NASDAQ:NEO) and Bio-Rad Laboratories (NYSE:BIO) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, profitability, institutional ownership and risk.

Risk & Volatility

NeoGenomics has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500. Comparatively, Bio-Rad Laboratories has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500.

Valuation & Earnings

This table compares NeoGenomics and Bio-Rad Laboratories' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NeoGenomics$408.83 million11.38$8.01 million$0.23183.17
Bio-Rad Laboratories$2.31 billion7.18$1.76 billion$7.0679.24

Bio-Rad Laboratories has higher revenue and earnings than NeoGenomics. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than NeoGenomics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for NeoGenomics and Bio-Rad Laboratories, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NeoGenomics011013.00
Bio-Rad Laboratories01302.75

NeoGenomics presently has a consensus price target of $37.1818, suggesting a potential downside of 11.75%. Bio-Rad Laboratories has a consensus price target of $577.75, suggesting a potential upside of 3.27%. Given Bio-Rad Laboratories' higher possible upside, analysts plainly believe Bio-Rad Laboratories is more favorable than NeoGenomics.

Profitability

This table compares NeoGenomics and Bio-Rad Laboratories' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NeoGenomics-1.33%0.73%0.51%
Bio-Rad Laboratories84.89%3.66%2.65%

Institutional and Insider Ownership

91.7% of NeoGenomics shares are held by institutional investors. Comparatively, 65.2% of Bio-Rad Laboratories shares are held by institutional investors. 6.5% of NeoGenomics shares are held by insiders. Comparatively, 27.5% of Bio-Rad Laboratories shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Bio-Rad Laboratories beats NeoGenomics on 10 of the 15 factors compared between the two stocks.


NeoGenomics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Cooper Companies logo
COO
Cooper Companies
1.8$348.79-0.4%$18.60 billion$2.65 billion62.40
Teladoc Health logo
TDOC
Teladoc Health
1.3$216.77-2.5%$17.98 billion$553.31 million-169.35Upcoming Earnings
Heavy News Reporting
Hologic logo
HOLX
Hologic
1.9$65.85-0.8%$17.05 billion$3.37 billion26.66
Teleflex logo
TFX
Teleflex
1.5$359.06-0.8%$16.70 billion$2.60 billion35.34Upcoming Earnings
Smith & Nephew logo
SNN
Smith & Nephew
2.0$38.05-1.2%$16.66 billion$5.14 billion18.65
Bio-Rad Laboratories logo
BIO
Bio-Rad Laboratories
1.5$559.43-0.6%$16.60 billion$2.31 billion8.67Upcoming Earnings
Quest Diagnostics logo
DGX
Quest Diagnostics
2.0$122.83-0.4%$16.50 billion$7.73 billion22.29Analyst Upgrade
Insider Selling
Heavy News Reporting
Insulet logo
PODD
Insulet
1.4$241.14-1.9%$15.83 billion$738.20 million861.25Decrease in Short Interest
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.6$136.48-3.6%$15.83 billion$219.75 million-18.03Upcoming Earnings
Analyst Downgrade
Analyst Revision
Steris logo
STE
Steris
1.7$185.95-0.2%$15.82 billion$3.03 billion38.66Increase in Short Interest
BIO.B
(BIO.B)
0.7$530.00-0.0%$15.73 billion$2.31 billion8.22Upcoming Earnings
Varian Medical Systems logo
VAR
Varian Medical Systems
1.2$171.86-0.0%$15.64 billion$3.23 billion55.98Upcoming Earnings
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
1.7$74.27-0.1%$15.33 billion$1.30 billion30.44
Catalent logo
CTLT
Catalent
0.9$92.41-0.8%$15.20 billion$3.09 billion83.25Increase in Short Interest
Exact Sciences logo
EXAS
Exact Sciences
1.2$99.61-3.4%$14.96 billion$876.29 million-93.97Upcoming Earnings
AVTR
Avantor
1.6$24.71-1.0%$14.25 billion$6.04 billion107.43Upcoming Earnings
Decrease in Short Interest
LVGO
Livongo Health
1.5$139.15-2.6%$14.14 billion$170.20 million-339.38Upcoming Earnings
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.7$77.50-0.5%$14.05 billion$1.70 billion117.42Upcoming Earnings
Heavy News Reporting
Cardinal Health logo
CAH
Cardinal Health
2.4$47.83-0.3%$14.03 billion$152.92 billion-3.83
GRIFOLS S A/S logo
GRFS
GRIFOLS S A/S
1.0$19.03-2.6%$13.08 billion$5.71 billion21.14High Trading Volume
Masimo logo
MASI
Masimo
1.2$234.16-0.9%$12.87 billion$937.84 million60.66Upcoming Earnings
Analyst Upgrade
Insider Selling
Novocure logo
NVCR
Novocure
1.5$127.06-3.8%$12.84 billion$351.32 million1,058.88Upcoming Earnings
Analyst Downgrade
PPD
PPD
1.9$36.15-1.2%$12.60 billion$4.03 billion36.89Upcoming Earnings
ABIOMED logo
ABMD
ABIOMED
1.2$272.60-1.8%$12.28 billion$840.88 million78.56Upcoming Earnings
Increase in Short Interest
Molina Healthcare logo
MOH
Molina Healthcare
1.3$206.73-0.1%$12.26 billion$16.83 billion15.91Upcoming Earnings
Heavy News Reporting
Elanco Animal Health logo
ELAN
Elanco Animal Health
2.1$30.41-2.6%$12.13 billion$3.07 billion-121.64Analyst Downgrade
argenx logo
ARGX
argenx
1.2$256.80-2.2%$12.07 billion$78.17 million-54.29Analyst Downgrade
Myokardia logo
MYOK
Myokardia
0.9$222.40-0.0%$11.79 billion$33.56 million-31.28
Qiagen logo
QGEN
Qiagen
1.2$50.58-3.0%$11.52 billion$1.53 billion1,686.00
Charles River Laboratories Intl. logo
CRL
Charles River Laboratories Intl.
1.1$229.09-1.9%$11.38 billion$2.62 billion42.19Upcoming Earnings
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.1$67.61-1.3%$11.20 billion$2.32 billion44.48Upcoming Earnings
DaVita logo
DVA
DaVita
1.3$89.61-0.1%$10.93 billion$11.39 billion14.13Upcoming Earnings
Icon logo
ICLR
Icon
1.6$202.23-0.5%$10.84 billion$2.81 billion33.71Earnings Announcement
Increase in Short Interest
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$137.26-0.2%$10.78 billion$380.83 million-19.55
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
2.3$9.48-3.6%$10.35 billion$16.89 billion4.10Analyst Upgrade
Analyst Revision
Quidel logo
QDEL
Quidel
1.2$241.98-3.1%$10.15 billion$534.89 million67.78Upcoming Earnings
Analyst Report
BIO-TECHNE logo
TECH
BIO-TECHNE
1.4$261.80-1.0%$10.10 billion$738.69 million45.22
DENTSPLY SIRONA logo
XRAY
DENTSPLY SIRONA
1.6$45.67-2.1%$9.98 billion$4.03 billion-198.57Increase in Short Interest
GH
Guardant Health
1.4$99.96-2.0%$9.94 billion$214.38 million-78.71Insider Selling
Universal Health Services logo
UHS
Universal Health Services
1.6$111.88-0.8%$9.51 billion$11.38 billion13.19
Henry Schein logo
HSIC
Henry Schein
1.4$63.62-1.7%$9.08 billion$9.99 billion15.83Decrease in Short Interest
Repligen logo
RGEN
Repligen
1.2$171.76-0.4%$9.02 billion$270.24 million296.14Upcoming Earnings
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.2$95.82-3.3%$8.94 billion$788.10 million45.41Analyst Revision
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$156.03-0.0%$8.25 billion$14.98 million-25.58
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.0$184.94-2.2%$8.24 billion$3.34 million-25.97Analyst Report
Heavy News Reporting
Amedisys logo
AMED
Amedisys
1.3$248.46-0.4%$8.07 billion$1.96 billion64.37Upcoming Earnings
Insider Selling
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
1.9$145.39-2.1%$8.06 billion$2.16 billion62.94Analyst Report
Galapagos logo
GLPG
Galapagos
1.3$123.10-7.1%$8.04 billion$1.00 billion78.91Analyst Upgrade
Heavy News Reporting
Penumbra logo
PEN
Penumbra
1.6$219.41-3.1%$7.92 billion$547.41 million756.61Upcoming Earnings
Increase in Short Interest
Mylan logo
MYL
Mylan
1.8$15.14-1.1%$7.83 billion$11.50 billion28.57Analyst Revision
This page was last updated on 10/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.